The stock market rebounded on Wednesday, with all major indices ending in the green as investors cheered the Federal Reserve’s decision to keep interest rates unchanged.

On Wednesday afternoon, the Fed kept rates steady at a range of 4.25 percent to 4.5 percent, saying that it was not in a hurry to cut rates and could still “wait and see” the impact of President Donald Trump’s tariff policies.

The Dow Jones rallied by 0.70 percent, the S&P 500 increased by 0.43 percent, and the Nasdaq grew by 0.27 percent.

Beyond the major indices, 10 firms stood out with strong gains, thanks to a flurry of fresh developments, including new partnerships, optimistic outlooks, and impressive earnings performance. In this article, we name Wednesday’s 10 best-performing stocks and detail the reasons behind their gains.

To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.

10. Webull Corporation (NASDAQ:BULL)

Webull Corporation saw its share prices rise by 8.77 percent to finish at $16.25 each as investor sentiment was boosted by the company’s new collaboration with Visa to enable real-time transactions in the US.

Under the partnership, accessing and transferring funds to and from Webull accounts will now be made easier in less than a minute with Visa Direct, compared to traditional methods like Automated Clearing House (ACH) transfers, which take days.

In a statement, Webull Corporation (NASDAQ:BULL) President Anthony Denier said: “We are proud to work with Visa and its expansive network to enhance opportunities within financial markets. There are several exciting uses for this new capability, which will allow us to integrate technology into traditional financial services in ways that better serve Webull’s customers.”

Webull Corporation (NASDAQ:BULL) is a financial services company offering trading platform services for various assets such as stocks and ETFs, among others. It also offers wealth management and investor education services.

9. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical grew its share prices by 9.18 percent on Wednesday to end at $17.60 apiece as investors cheered the company’s 9th consecutive quarter of impressive revenue performance.

In its earnings release, Teva Pharmaceutical Industries Limited (NYSE:TEVA) said it achieved a 2-percent increase in revenues in the first three months of the year at $3.89 billion from the $3.82 billion registered in the same period last year, thanks to the higher contribution from Austedo and Uzedy’s US operations, coupled with sales from its generic products across all other segments.

The strong figures pushed the company to profitability during the quarter, having swung to an attributable net income of $214 million versus a $139 million net loss year-on-year.

Looking ahead, Teva Pharmaceutical Industries Limited (NYSE:TEVA) posted a generally optimistic outlook for its business, saying that US tariffs are expected to have an immaterial impact.

For the full year 2025, the company expects revenues to settle anywhere between $16.8 billion and $17.2 billion.

8. Nebius Group N.V. (NASDAQ:NBIS)

Nebius Group jumped by 9.62 percent on Wednesday to end at $27.45 apiece as investor sentiment was buoyed by billionaire Jeff Bezos’ investment in the company.

In a statement on Wednesday, Nebius Group N.V. (NASDAQ:NBIS) said that its AI data solutions business Toloka, welcomed a strategic investment by Bezos Expeditions, with participation from Shopify’s chief technology officer, Mikhail Parakhin.

The investment marked a pivotal step for Toloka as it is expected to scale up and sharpen its strategic focus amid accelerating global demand for reliable, high-quality AI data solutions.

Upon completion, Parakhin is set to assume the role of the executive chairman for the newly constituted board of directors.

According to Nebius Group N.V. (NASDAQ:NBIS), it will continue to hold a majority stake in Toloka, but will give up the majority of its voting power in Toloka as it aims to give the latter greater independence while it focuses on its core AI infrastructure business.

7. The Walt Disney Company (NYSE:DIS)

Walt Disney surged by 10.76 percent on Wednesday to end at $102.09 apiece following an impressive earnings performance for the first semester of fiscal year 2025.

In its latest earnings release, The Walt Disney Company (NYSE:DIS) said that it swung to an attributable net income of $3.275 billion in the second quarter ending March 2025, from a net loss of $20 million in the same period last year. This pushed the company’s six-month attributable net income to expand by 208 percent to $5.829 billion from $1.891 billion year-on-year.

Revenues for the second quarter alone rose by 6.88 percent to $23.6 billion from $22.08 billion, while revenues for the first half grew by 5.9 percent to $48.3 billion from $45.6 billion year-on-year.

Following the strong figures, The Walt Disney Company (NYSE:DIS) CEO Robert Iger said that the mass media and entertainment conglomerate remains optimistic about its business outlook for the remainder of the fiscal year.

6. Coupang, Inc. (NYSE:CPNG)

Coupang Inc. saw its share prices surge by 10.83 percent on Wednesday to end at $26.60 apiece as investors cheered its improved earnings performance for the first quarter of the year.

In a statement, Coupang, Inc. (NYSE:CPNG) said that net income attributable to shareholders during the period expanded by 2,040 percent to $107 million from $5 million in the same period last year, while net revenues increased by 11 percent to $7.908 billion from $7.114 billion year-on-year.

Additionally, Coupang, Inc. (NYSE:CPNG) announced that its board of directors recently approved a share buyback program amounting to $1 billion. The initiative was part of its broader capital allocation strategy to provide shareholder value. The buyback program only covers its Class A common shares.

Coupang, Inc. (NYSE:CPNG) is a technology company providing retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch.

5. Tempus AI, Inc. (NASDAQ:TEM)

Tempus AI saw its share prices increase by 12.59 percent on Wednesday to finish at $58.76 apiece as investors loaded portfolios following an optimistic outlook guidance, offsetting a dismal earnings performance during the past quarter.

In its latest earnings release, Tempus AI, Inc. (NASDAQ:TEM) said that it is targeting $1.25 billion in revenues for the consolidated Tempus and Ambry Genetics for full-year 2025, which would represent an 80 percent growth year-on-year.

During the first quarter, Tempus AI, Inc. (NASDAQ:TEM) widened its net loss by 5.1 percent to $68 million from $64.7 million in the same period last year.

Revenues, however, were higher by 75.86 percent to $255 million from $145.8 million, with Genomics contributing $193.8 million, or an 88.9 percent increased contribution year-on-year.

“The business is performing well with revenues growing, margins improving, and our costs remaining in check, allowing us to demonstrate significant year-over-year operating leverage,” said Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky.

“Our strategic investments in AI have us uniquely positioned to advance what is possible in diagnostics and drug development, as evidenced by our announcement to build the largest foundation model in oncology with AstraZeneca and Pathos,” he added.

4. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Halozyme Therapeutics saw its share prices soar by 18.12 percent on Wednesday to end at $70.14 apiece as investor sentiment was buoyed by its impressive earnings performance in the first quarter of the year.

During the period, Halozyme Therapeutics, Inc. (NASDAQ:HALO) netted $118 million, higher by 53.6 percent than the $76.8 million registered in the same period last year.

Revenues increased by 35 percent to $264.86 million from $195.88 million year-on-year, thanks to higher royalty revenue and increased sales from rHuPH20, an enzyme that facilitates SC delivery of high-dose, high-volume therapeutics.

Following the strong quarter, Halozyme Therapeutics, Inc. (NASDAQ:HALO) raised its revenue outlook guidance for full-year 2025, now targeting a range of $1.2 billion to $1.28 billion, as compared with the $1.15 billion to $1.225 billion previously.

Of the total, royalty revenues are expected to reach between $750 million and $785 million, higher than the $725 million to $750 million as previously targeted.

3. AvidXchange Holdings, Inc. (NASDAQ:AVDX)

AvidXchange jumped by 18.78 percent on Wednesday to close at $9.74 apiece as investors snapped up shares following news that it is set to be acquired by investment firm TPG and Corpay for $2.2 billion.

In a statement, Corpay said it inked a definitive agreement with the two parties for the acquisition of AvidXchange Holdings, Inc. (NASDAQ:AVDX) shares at a price of $10 apiece.

Under the deal, TPG will own a majority stake in AvidXchange, while Corpay will take the remaining 33 percent.

Corpay will also have the option to increase its stake in AvidXchange to as much as 100 percent by 2028.

The transaction is expected to be completed in the fourth quarter of 2025, subject to customary closing conditions.

“We couldn’t pass up the opportunity to participate in this transaction and invest in a large, complementary corporate payments business,” said Corpay Chairman and CEO Ron Clarke.

2. Elanco Animal Health Incorporated (NYSE:ELAN)

Elanco Animal Health saw its share prices soar by 26.29 percent on Wednesday to end at $12.01 apiece following an impressive net income performance coupled with an optimistic outlook for the rest of the year.

In its latest earnings release, Elanco Animal Health Incorporated (NYSE:ELAN) said net income for the first quarter of the year expanded by 109 percent to $67 million from $32 million in the same period last year, despite total revenues dipping by 1 percent to $1.19 billion from $1.2 billion year-on-year, weighed down by an unfavorable impact from the aqua divestiture coupled with foreign exchange losses during the quarter.

Despite this, Elanco Animal Health Incorporated (NYSE:ELAN) remains optimistic for the rest of the year, having raised its revenue guidance to a range of $4.51 billion to $4.58 billion.

Net loss, on the other hand, is expected to widen to a range of $7 million to $35 million.

“We are raising our 2025 full-year revenue guidance and maintaining our adjusted EBITDA and adjusted EPS ranges,” said CFO Todd Young.

“On tariffs, we have taken several intervention actions, positioning us well to cover potential impacts with or without the pharmaceutical exemption,” he added.

1. Oscar Health, Inc. (NYSE:OSCR)

Oscar Health skyrocketed by 30.22 percent on Wednesday to close at $17.02 per share after reporting a strong earnings performance in the past quarter.

During the period, Oscar Health, Inc. (NYSE:OSCR) said it achieved a 55-percent increase in net income attributable to the company, at $275 million versus the $177 million in the same period last year.

Revenues were also higher by 42 percent to $3.05 billion from $2.14 billion year-on-year.

During the quarter, its membership increased by 40.7 percent to 2.04 million from 1.4 million in the same period a year ago.

“We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners,” said Oscar Health, Inc. (NYSE:OSCR) CEO Mark Bertolini, adding that the company has reaffirmed its full year 2025 outlook across all metrics.

Oscar Health, Inc. (NYSE:OSCR) expects revenues between $11.2 billion and $11.3 billion and operational earnings of $225 million to $275 million.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.